Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 11:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Razadyne Clear all
Completed Phase 2 Interventional Results available

Effect of Galantamine on Short-term Abstinence

NCT01669538
View directory record Official record
Conditions
Tobacco Use Disorder
Interventions
Galantamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Effect of Galantamine on Inflammation and Cognition

NCT03384784
View directory record Official record
Conditions
HIV Associated Cognitive Motor Complex
Interventions
Galantamine, Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
30 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder

NCT00195845
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Galantamine, Placebos
Drug
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Not applicable Interventional Results available

Cognitive Enhancement as a Target for Cocaine Pharmacotherapy

NCT01531153
View directory record Official record
Conditions
Addiction
Interventions
Galantamine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 60 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Not applicable Interventional Results available

A Study to Help People Quit Smoking.

NCT01880099
View directory record Official record
Conditions
Nicotine Dependence
Interventions
placebo, Galantamine 8mg, Galantamine 16mg
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 22, 2020 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Not applicable Interventional

Galantamine-CR and Cognitive Dysfunction in Bipolar Disorder

NCT00181636
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Galantamine-CR
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2007 · Synced Sep 9, 2026, 11:15 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Galantamine in the Treatment of Post-Traumatic Headache

NCT00219869
View directory record Official record
Conditions
Post-Traumatic Headache, Head Trauma,Closed, Retention Disorders,Cognitive
Interventions
Galantamine
Drug
Lead sponsor
Rapoport, Alan, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2005 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 4 Interventional

Efficacy of Galantamine to Treat Schizophrenia

NCT00232349
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorder
Interventions
galantamine
Drug
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Other
Eligibility
18 Years to 60 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Jul 30, 2008 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Subarachnoid Hemorrhage Recovery And Galantamine

NCT02872857
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Placebo, 8mg galantamine twice daily, 12mg galantamine twice daily
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2021 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Not applicable Interventional Results available

Galantamine Effects on Cognitive Function in Abstinent Cocaine Users

NCT00606801
View directory record Official record
Conditions
Cocaine Abuse
Interventions
Galantamine, placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 14, 2021 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Racial Differences in Vagal Control of Glucose Homeostasis

NCT02365285
View directory record Official record
Conditions
Obesity
Interventions
Galantamine, Placebo Oral Capsule, Intralipid, Heparin
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2 Interventional Results available

Use of Galantamine and CDP-choline (Citicoline) to Treat Adults With Schizophrenia

NCT00509067
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine, CDP-choline, Placebo, risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole
Drug
Lead sponsor
Georgetown University
Other
Eligibility
18 Years to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 10, 2018 · Synced Sep 9, 2026, 11:15 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Galantamine Executive Function in Parkinson's Disease

NCT00211588
View directory record Official record
Conditions
Parkinson's Disease
Interventions
galantamine
Drug
Lead sponsor
Memorial Hospital of Rhode Island
Other
Eligibility
60 Years to 85 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Pawtucket, Rhode Island
Source: ClinicalTrials.gov public record
Updated May 6, 2007 · Synced Sep 9, 2026, 11:15 AM EDT
Active, not recruiting Phase 1 Interventional

Vagal Stimulation in POTS

NCT03124355
View directory record Official record
Conditions
Postural Tachycardia Syndrome
Interventions
placebo sugar pill, Pyridostigmine Pill, Galantamine Pill, Vagal stimulation, Sham vagal stimulation
Drug · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Galantamine for Cognition in People With Schizophrenia

NCT00320736
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
galantamine
Drug
Lead sponsor
North Suffolk Mental Health Association
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2009 · Synced Sep 9, 2026, 11:15 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Enhancing Parasympathetic Activity to Improve Endothelial Dysfunction, Vascular Oxidative Stress in African Americans

NCT04769206
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Galantamine, Placebo, TENS 7000
Drug · Device
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Low-Dose Galantamine to Potentiate the Attention-Enhancing Effects of Low-Dose Nicotine

NCT02420327
View directory record Official record
Conditions
Basic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor
Interventions
Placebo patch & placebo capsule, Placebo patch & galantamine capsule, Nicotine patch & placebo capsule, Nicotine patch and galantamine capsule
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Catonsville, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 3, 2019 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Galantamine Effects on Cognitive Function in Marijuana Users

NCT00969696
View directory record Official record
Conditions
Memory
Interventions
Placebo, Galantamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 55 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 24, 2012 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 2Phase 3 Interventional

Galantamine for Cognitive Deficits in Schizophrenia

NCT00463879
View directory record Official record
Conditions
Schizophrenia
Interventions
Galantamine
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 11, 2007 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 4 Interventional

Galantamine Augmentation of Escitalopram for Treatment of Depression

NCT00423969
View directory record Official record
Conditions
Depression
Interventions
Galantamine, Escitalopram
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 60 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 17, 2007 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Phase 2 Interventional

Cognitive REmediation After Trauma Exposure Trial = CREATE Trial

NCT01416948
View directory record Official record
Conditions
Posttraumatic Stress Disorder, Traumatic Brain Injury
Interventions
Methylphenidate Hydrochloride 20 mg, Placebo Capsule, Galantamine 12 mg
Drug
Lead sponsor
INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
San Diego, California • Boston, Massachusetts • Manchester, New Hampshire + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2013 · Synced Sep 9, 2026, 11:15 AM EDT
Completed Phase 4 Interventional

A Double-Blind Comparison of Galantamine HBr and Placebo in Adults With Attention Deficit Hyperactivity Disorder

NCT00181675
View directory record Official record
Conditions
ADHD
Interventions
galantamine HBr
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 58 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 22, 2010 · Synced Sep 9, 2026, 11:15 AM EDT
Terminated Not applicable Interventional Results available

Comparative Research of Alzheimer's Disease Drugs

NCT01362686
View directory record Official record
Conditions
Dementia, Alzheimer's Disease
Interventions
Donepezil, Galantamine, Rivastigmine
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
5
States / cities
Fishers, Indiana • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Sep 9, 2026, 11:15 AM EDT
Recruiting Phase 4 Interventional

A Study of Zunveyl on Safety, Tolerability, Neuropsychiatric Symptoms, and Caregiver Distress in Alzheimer's Disease (RESOLVE)

NCT07633470
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Zunveyl®
Drug
Lead sponsor
Alpha Cognition, Inc
Industry
Eligibility
50 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
14
States / cities
Orange, California • Aventura, Florida • Hialeah, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 9, 2026, 11:15 AM EDT